Innate Pharma prices €30M share offering to fund lead cancer drug
What's the deal? Innate Pharma priced a €30 million share offering, issuing 17,647,059 new ordinary shares at €1.70 each. The French biotech, listed on Euronext Paris and Nasdaq, expects net proceeds of €27.6 million after commissions and expenses.
Who's in? Stifel acted as sole global coordinator, with BTIGDealroom has a profile for this one. Try Dealroom → joining as joint bookrunner. Existing shareholder Bpifrance Participations committed to a €3 million order in the book.
What's the endgame? Innate plans to use the proceeds first to advance clinical development of IPH4502, its lead candidate, then its preclinical antibody-drug conjugate portfolio and general working capital.
The details: The €1.70 price matched the volume-weighted average over the five trading sessions before pricing, less a 15% discount. The offering closes on 18 August 2026, when the new shares begin trading on Euronext Paris.
The signal: The raise is a modest one, sitting in the lower fifth percentile by deal size. For a clinical-stage biotech, tapping public markets for capital keeps the lead programme moving without waiting on a larger financing.
Read more: FinanzNachrichten
Image credit: History at NIH
